Publication: Transgender People and HIV Prevention: What We Know and What We Need to Know, a Call to Action
Open/View Files
Date
2016
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
JAIDS Journal of Acquired Immune Deficiency Syndromes
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Mayer, Kenneth H., Beatriz Grinsztejn, and Wafaa M. El-Sadr. 2016. “Transgender People and HIV Prevention: What We Know and What We Need to Know, a Call to Action.” Journal of Acquired Immune Deficiency Syndromes (1999) 72 (Suppl 3): S207-S209. doi:10.1097/QAI.0000000000001086. http://dx.doi.org/10.1097/QAI.0000000000001086.
Research Data
Abstract
Abstract: Transgender people have been disproportionally affected by HIV, particularly transgender women. Their increased vulnerability to HIV is due to multiple issues, including biological (eg, increased efficiency of HIV transmission through receptive anal sex), epidemiological (eg, increased likelihood of having HIV-infected partners), structural (eg, social stigma limiting employment options), and individual factors (eg, internalized stigma leading to depression and substance use and risk-taking behaviors). There have been limited culturally appropriate HIV prevention interventions for transgender people, with many key prevention studies (eg, the iPrEx PrEP study) enrolling transgender women in a study focusing on men who have sex with men. This has resulted in limited understanding of the optimal ways to decrease transgender people's risk for HIV acquisition. The current supplement of JAIDS is designed to review what is known about HIV prevention for transgender people and to highlight new insights and best practices. The study reviews recent epidemiologic data, the pharmacology of HIV prophylactic agents in individuals who may be using exogenous hormones, and several recent multi-component interventions designed to address the lived experience of transgender people. Additionally, the study reviews the work going on at the NIH to address transgender health in general and HIV prevention in specific, as well as two important papers related to clinical trial design issues and the ethical conduct of research in this frequently disenfranchised population. It is the hope of the HIV Prevention Trials Network (HPTN) that this supplement will promote new knowledge around transgender health and the requisite issues that need to be addressed in order to conduct optimal clinical trials. The ultimate hope is that the information distilled in this supplement will inform investigators, clinicians, and public health officials in order to design further research to develop optimal prevention interventions for transgender people and to implement these interventions in ways that are culturally congruent and health promoting.
Description
Other Available Sources
Keywords
HIV prevention, transgender, HIV/AIDS
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service